Background
Phase III, open-label, 2×2 factorial RCT (GHSG HD11). 1,395 patients with early-stage unfavorable classical Hodgkin lymphoma (GHSG criteria: stage IA–IIB with risk factors: large mediastinal mass, extranodal disease, elevated ESR, or ≥3 nodal areas). Compared chemotherapy intensity (4×ABVD vs 4×BEACOPP baseline) and radiation dose (30 Gy vs 20 Gy IFRT) in a 2×2 factorial design.
Interventions and follow up
Arm A (reference): 4×ABVD + 30 Gy IFRT
Other arms: 4×ABVD + 20 Gy IFRT; 4×BEACOPP baseline + 30 Gy IFRT; 4×BEACOPP baseline + 20 Gy IFRT
Primary endpoint: Freedom from treatment failure (FFTF)
Median follow up: 81 months
Other arms: 4×ABVD + 20 Gy IFRT; 4×BEACOPP baseline + 30 Gy IFRT; 4×BEACOPP baseline + 20 Gy IFRT
Primary endpoint: Freedom from treatment failure (FFTF)
Median follow up: 81 months
Results
5-year FFTF (4×ABVD + 30 Gy, reference): 85.0%
4×ABVD + 20 Gy: 81.1% — 20 Gy inferior to 30 Gy when ABVD used
4×BEACOPP baseline + 30 Gy: 87.0%
4×BEACOPP baseline + 20 Gy: 86.8% — 20 Gy non-inferior to 30 Gy with BEACOPP
5-year OS: 94–95% all arms — no significant differences
4×ABVD + 20 Gy: 81.1% — 20 Gy inferior to 30 Gy when ABVD used
4×BEACOPP baseline + 30 Gy: 87.0%
4×BEACOPP baseline + 20 Gy: 86.8% — 20 Gy non-inferior to 30 Gy with BEACOPP
5-year OS: 94–95% all arms — no significant differences
Adverse events
Hematologic: BEACOPP baseline arms higher grade ≥3 toxicity (neutropenia ~70% vs ~35% with ABVD)
Other: ABVD + 30 Gy pulmonary/cardiac risk from bleomycin + mediastinal RT; secondary malignancies non-significantly higher with BEACOPP at this follow-up
Other: ABVD + 30 Gy pulmonary/cardiac risk from bleomycin + mediastinal RT; secondary malignancies non-significantly higher with BEACOPP at this follow-up
Conclusions
4×BEACOPP baseline + 20 Gy IFRT was non-inferior to 4×ABVD + 30 Gy IFRT for early-stage unfavorable HL, establishing that BEACOPP allows reduction of radiation dose. 4×ABVD + 20 Gy was inferior to 4×ABVD + 30 Gy, mandating that if ABVD is used, 30 Gy radiation is required.
Key Limitations
Radiation volumes were IFRT (larger than contemporary INRT/ISRT), limiting applicability of radiation-dose findings to modern practice. BEACOPP baseline is less commonly used than BEACOPP escalated for unfavorable HL. Non-inferiority interpretation requires caution — BEACOPP arms numerically showed better FFTF. Long-term toxicity (secondary malignancies, cardiovascular events) favors reduced RT doses regardless of chemotherapy choice.
Clinical Context
HD11 contributed to the evidence that 4 cycles of chemotherapy are needed for unfavorable early-stage HL (vs 2 cycles for favorable). The subsequent HD14 trial established 2×BEACOPP escalated + 2×ABVD + 30 Gy IFRT as the GHSG standard for unfavorable early-stage HL, showing superiority over 4×ABVD. Combined with HD17, current GHSG/ESMO-aligned approaches allow PET-guided omission of RT after the 2+2 regimen in PET-negative patients.
References